Abstract 4024: Overcoming ALK resistance with covalent cysteine-reactive inhibitors in lung cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4024
Abstract: The EML4-ALK fusion gene is the main oncogenic driver in 5% of non-small cell lung cancer and has been effectively targeted using ALK-specific tyrosine kinase inhibitors. While survival rates have improved steadily with each new… read more here.
Keywords: alk; cysteine reactive; cancer; alk resistance ... See more keywords
An artificial intelligence approach to variant calling of ALK resistance mutations.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.3079
Abstract: 3079 Background: ALK tyrosine kinase inhibitors (TKIs) are effective in treating advanced anaplastic lymphoma kinase (ALK) fusion-positive non-small-cell lung cancers (NSCLC), and specific ALK variants are associated with the development of resistance to specific TKIs.… read more here.
Keywords: artificial intelligence; alk; alk resistance; model ... See more keywords